investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
53BP1-Mediated Regulation of DNA Repair and Chemoresistance
Shridar Ganesan
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Shridar Ganesan
Rutgers University
New Brunswick, United States
Related projects
William C Hahn
Regulation and function of IKKe in breast cancer initiation and maintenance
Breast
Pathology
Areti Strati
Molecular Characterization of CTC in Prostate Cancer
Breast
Philip Tofilon
Radiation-induced translational control of gene expression
Breast
Radiation Oncology
Tiffany Y Hsu
Elucidating the functions of Bud31, an essential gene in Myc-driven breast cancer
Breast
Maxwell Lee
Genetics and Epigenetics of Cancer
Breast
Jing Yang
Regulation of Tumor Invasion and Metastasis by Matrix Stiffness
Breast
Akhilesh Pandey
Personalized Therapy of Hormone Refractory Breast Cancer
Breast
Robert H. Singer
Mechanism of Actin mRNA Localization and Localized Translation in Neurons
Breast
Fraser Symmans
Development of A Predictive Genomic Diagnostic Test for Survival Benefit from Everolimus (mTOR Inhibitor) Combined with Endocrine Therapy for Metastatic HR+/HER- Breast Cancer
Breast